Current treatment for chronic hepatitis C virus/HIV-infected individuals: The role of pegylated interferon-alpha and ribavirin

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 483-490

  Bhagani, Sanjay ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

HIV hepatitis C co infection; pegylated interferon alpha; ribavirin; treatment

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; ZIDOVUDINE;

ANEMIA; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FATTY LIVER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LEUKOPENIA; LIVER FIBROSIS; MIXED INFECTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80054908771     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834bd257     Document Type: Review

References (87)

1. Joshi D, O'Grady J, Dietrich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198-1209.
2. Opersalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment and new therapeutics. Curr HIV/AIDS Rep 2011; 8:12-22.
3. Bruno R, Galastri S, Sacchi P, et al. Gp120 modulates the biology of human hepatic stellate cell: a link between HIV infection and liver fibrogenesis. Gut 2010; 59:513-520.
4. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects hepatic stellate cells and promotes collagen 1 andmonocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52:612-622.
5. Chung RT, Anderson J, Volberding P, et al. Peginterferon-alpha-2a plus ribavirin versus interfern-alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459. (Pubitemid 38988594)
6. Torriani FJ, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon-alpha- 2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
7. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Assoc 2004; 292:2839-2848. (Pubitemid 39628231)
8. Lissen E, Clumek N, Sola R, et al. Histological response to PegIFN alpha-2a (40 kD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20:2175-2181. (Pubitemid 44684708)
9. Ingiliz P, Valantin M, Petrosi P, et al. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV co-infected patients: a prospective repeated liver biopsy analysis. J Hepatology 2011. [Epub ahead of print]
10. Macias J, del Valle J, Rivero A, et al. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother 2010; 65:2204-2211.
11. Garcia-Alvarez M, Berenguer J, Micheloud D, et al. Sustained virological response decreases serum markers of angiogenesis, inflammation and fibrosis in HIV/HCV-coinfected patients on hepatitis C therapy. AIDS Patient Care STDS 2011; 25:131-133.
12. De Bona A, Galli L, Gallatta G, et al. Rate of cirrhosis progression reduced in HIV/HCV co-infected nonresponders to anti-HCV therapy. New Microbiol 2007; 30:259-264. (Pubitemid 47264885)
13. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related mortality in patients co-infected with human immunodeficiency virus and hepatitis C. Hepatology 2009; 50:407-413.
14. Barreiro P, Labarga P, Martin-Carbonero L, et al. Sustained virological response following HCV therapy is associated with nonprogression of liver fibrosis in HCV/HIV co-infected patients. Antiviral Ther 2006; 11:869-877. (Pubitemid 44736178)
15. Tuma P, Medrano J, Resino S, et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or Cin the era of HAART. Antiviral Ther 2010; 15:881-886.
16. Miralles P, Bellon JM, Alvarez E, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
17. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic HCV in HIV-infected patients. J Infect Dis 2007; 196:670-676. (Pubitemid 47293847)
18. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alpha and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15:i-xii, 1-210.
19. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Effects of hepatitis C virus treatment in fibrosis progression (FP) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus. J Hepatol 2007; 46:613-619. (Pubitemid 46402952)
20. Sherman KE, Anderson JW, Butt AA, et al. Sustained long term antiviral maintenance therapy in HCV/HIV co-infected patients (SLAM-C). J Acquir Immune Defic Syndr 2010. [Epub ahead of print]
21. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429-2441.
22. Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53:1100-1108.
23. Merchante N, Rivero A, de Los Santos-Gil I, Merino D, et al. Insulin resistance id associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009; 58:1654-1660.
24. Cacoub P, Carrat E, Bedosa P, et al. Insulin resistance impairs sustained virological response to pegylated interferon plus ribavirin in HIV-hepatitis C virus co-infected patients: HOMAVIC-ANRS HC02 study. Antiviral Ther 2009; 14:839-845.
25. Nashta P, Gatti F, Puoti M, et al. Insulin resistance impairs virological response in HIV/Hepatitis co-infected patients on peginterferon-alpha-2a. AIDS 2008; 22:857-861. (Pubitemid 351563835)
26. Vachon ML, Factor SH, Branch AD, et al. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HCV/HIV co-infected patients. J Hepatol 2011; 54:41-47.
27. Merchante N, de los Santos-Gil I, Merino D, et al. Insulin resistance and HCV virological response to peg-interferon with ribavirin in HIV/HCV co-infected patients. J Hepatol 2010; 52:305-307.
28. Donato C, Cingolani A, Pennetti C, De Luca A. Insulin resistance and HCV virological response to peg-interferon with ribavirin in HIV/HCV co-infected patients. J Hepatol 2010; 52:305-307.
29. Cesari M, Caromma I, Antinori S, et al. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C (HCV) virus treatment in HIV/HCV co-infected individuals. HIV Med 2009; 10:580-585.
30. Petit JM, Carrat F, Duong M, et al. Response to anti-HCV therapy in HIV-HCV co-infected patients; does lipid profile really have an effect? Antiviral Ther 2010; 15:797-800.
31. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40 kD) plus ribavirin in patients with HIV/hepatitis C virus co-infection. J Acquir Defic Syndr 2008; 47:36-49. (Pubitemid 351619367)
32. Avidan NU, Goldstein D, Rozenberg L, et al. Hepatitis C viral kinetics during treatment with peg-IFN-alpha-2b in HIV/HCV co-infected patients as a function of baseline CD4+ counts. J Acquir Defic Syndr 2009; 52:452-458.
33. Rohrbach J, Robinson M, Harcourt G, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59:1252-1258.
34. Valerio L, Yazdanpanah Y, Poizot-Martin I, et al. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus co-infected patients. J Acquir Defic Syndr 2008; 47:50-55. (Pubitemid 351619368)
35. Mira JA, Gutierrez-Valencia A, Gil Ide L, et al. Efficacy and safety of pegylated interferon plus ribavirin in HIV and Hepatitis C virus co-infected patients with advanced immunosuppression. Clin Infect Dis 2009; 49:e84-91.
36. Reiberger T, Payar BA, Kosi L, et al. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin in HIV-hepatitis C coinfected patients. J Infect Dis 2011; 203:1802-1806.
37. Dahari H, Layden-Almer J, Perelson AS, Layden TJ. Hepatitis C viral kinetics in special populations. Curr Hepat Rep 2008; 7:97-105.
38. Laufer N, Bolcic F, Rolon MJ, et al. HCV RNA decline in the first 24 h exhibits a high negative predictive value of sustained virological responses in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antiviral Res 2011; 90:92-97.
39. Araujo ES, Dahari H, Neumann AU, et al. Very early prediction of response to HCV treatment with PEG-IFN-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Viral Hepat 2011; 18:e52-e60.
40. Rodriguez-Torres M, Torriani F, Rockstroh J, et al. Degree of viral decline early in treatment predicts sustained virological response in HIV-HCV coinfected patients treated with peginterferon alpha-2a and ribavirin. HIV Clin Trials 2010; 11:1-10.
41. Payan C, Pirert A, Marand P, et al. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG FN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut 2007; 56:1111-1116. (Pubitemid 47123242)
42. Nunez M, Miralles C, Berdun MA, et al. Role of weight based ribavirin and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESO trial. AIDS Hum Retroviruses 2007; 23:972-982. (Pubitemid 47492337)
43. Martin-Carbonero L, Nunez M, Manno A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008; 22:15-21. (Pubitemid 350294873)
44. Van Den Eyde E, Crespo M, Esteban J, et al. Response-guided therapy for chronic hepatitis C virus infection in patients HIV: a pilot trial. Clin Infect Dis 2009; 48:1152-1159.
45. Shea DO, Tuite H, Farrell G, et al. Role of rapid virological response in prediction of sustained virological response to PEG-IFN plus ribavirin in HCV/HIV co-infected patients. J Viral Hepat 2008; 15:482-489. (Pubitemid 351798985)
46. Crespo M, Esteban JI, RIbera E, et al. Utility of 4 week response to tailor treatment duration in hepatitis C virus genotype 3/HIVco-infected patients. AIDS 2007; 21:477-481.
47. Soriano V, Miralles C, Berdun MA, et al. Premature treatment discontinuation in HIV/HCV patients recieving pegylated interferon plus weight-based ribavirin. Antivir Ther 2007; 12:469-476. (Pubitemid 47041145)
48. Van den Eyde E, Tiraboschi JM, Tural C, et al. Ability of 12 week response to predict long term outcome in genotype 1 Hepatitis C virus/HIV co-infected patients. AIDS 2010; 24:975-982.
49. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C infection. Nature 2004; 432:922-924. (Pubitemid 40037156)
50. Nunez M, Camino N, Ramos B, et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antiviral Ther 2005; 10:657-662. (Pubitemid 41224957)
51. Ramos B, Nunez M, Rendon A, et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV co-infected patients. J Viral Hepat 2007; 14:387-391. (Pubitemid 46744049)
52. Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72:349-361. (Pubitemid 35178861)
53. Rendon A, Nunez M, Romero M, et al. Early monitoring of ribavirin concentrations may predict anaemia and early virological response in HIV/hepatitis C co-infected patients. J Acquir Immune Defic Syndr 2005; 39:401-405. (Pubitemid 41003783)
54. Aguilar Marucco D, Gaonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 2008; 61:919-924. (Pubitemid 351426079)
55. Breilh D, Djabarouti S, Trimoulet P, et al. Ribavirin trough concentration predicts sustained virological response to peginterferon alpha 2a plus ribavirin in previously treated HCV-HIV-co-infected patients. J Acquir Immune Defic Syndr 2009; 52:428-430.
56. Marello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predicts hepatitis C (HCV) relapse in HIV-HCV co-infected patients treated for chronic hepatitis C. Antimicrob Agents Chemother 2010; 54:1647-1649.
57. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients with HIV and HCV. J Med Virol 2008; 80:1523-1529.
58. Dahari H, Markatou M, Zeremzki M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47:23-30. (Pubitemid 46817685)
59. Crespo M, Pou L, Esteban J, et al. Early monitoring of ribavirin serum concentration is not useful to optimise hepatitis C virus treatment in HIVcoinfected patients. Antiviral Ther 2007; 12:1217-1223.
60. Bani-Sadr F, Denoeud L, Morand P, et al. Early virological failure in HIVcoinfected hepatitis C patients treated with peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125. (Pubitemid 46684453)
61. Vispo E, Barreiro P, Pineda J, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis Ctreated with abacavir. Antivir Ther 2008; 13:429-437. (Pubitemid 352016736)
62. Mira JA, Lopes-Cortez LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nuvleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
63. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylatedinterferon and weight-adjusted ribavirin. Antivir Ther 2008; 13:953-957.
64. Pineda JA, Mira JA, de los Santos Gil I, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354. (Pubitemid 350168332)
65. Berenguer J, von Wichmann M, Quereda C, et al. Effect of accompanying antiretroviral drugs on virological response to PEG-IFN and ribavirin in HIV/ HCV co-infected patients. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. February 16-19, 2010 (abstract 663).
66. Amorosa VK, Slim J, Mounzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral- treated HIV-infected patients. Antivir Ther 2010; 15:91-99.
67. Tural C, Galeras JA, Planas R, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C (HCV)-monoinfected and HIV-HCV-coinfected patients. Antivir Ther 2008; 13:1047-1055.
68. Mauss S, Valenti W, Depamphilis J, et al. Risk factors hepatic decompensation in patients with HIV/HCV co-infection and liver cirrhosis during interferonbased therapy. AIDS 2004; 18:F21-F25. (Pubitemid 39179625)
69. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005; 41:1806-1809. (Pubitemid 41759869)
70. Bani-Sadr F, Lapidus N, Melchior JC, et al. Severe weight loss in HIV/HCV coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat 2008; 15:255-260. (Pubitemid 351326906)
71. Lo Re V 3rd, Kostman JR, Gross R, et al. Incidence and risk factors for weight loss during dual HIV/hepatitis therapy. J Acquir Immune Defic Syndr 2007; 44:344-350. (Pubitemid 46328353)
72. Mira J, Lopes-Cortes LF, Merino D, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment. Antiviral Ther 2007; 12:1225-1235.
73. Behler CM, Vittinghoff E, Lin F, et al. Haematological toxicity associated with interferon-based hepatitis C therapy in HIV type1-coinfected patients. Clin Infect Dis 2007; 44:1375-1383. (Pubitemid 46717302)
74. Nunez M, Ocampo A, Aquirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008; 15:363-369. (Pubitemid 351473628)
75. Butt AA, Umbleja T, Anderson JW, et al. The incidence, predictors and management of anaemia and its association with virological response in HCV/HIV coinfected patients treated with long-term pegylated interferon alpha 2a and ribavirin. Aliment Pharmacol Ther 2011; 33:1234-1244.
76. Mac Nicholas R, Norris S. Optimising SVR and management of the haematological side-effects of peginterferon/ribavirin antiviral therapy for HCV: role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 2010; 31:929-937.
77. Kevans D, Farrell G, Hopkins S, et al. Haematological support during peginterferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia 2007; 13:593-598. (Pubitemid 47338002)
78. Sulkowski MS, Shiffman ML, Afdhal N, et al. Hepatitis C Virus treatmentrelated anemia is associated with higher sustained virological response rates. Gastroenterology 2010; 139:1602-1611.
79. Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebocontrolled trial. Psychosomatics 2010; 51:401-408.
80. Quereda C, Corral I, Moreno A, et al. Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV co-infected patients. J Acquir Immune Defic Syndr 2008; 49:61-63.
81. Tural C, Sola R, Rubio R, et al. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C viral kinetics in HIV/HCV coinfected patients: the CORAL-1 multicentre pilot study. J Viral Hepat 2007; 14:704-713. (Pubitemid 47414930)
82. Vispo E, Labarga P, Guardiola JM, et al. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C. AIDS Res Hum Retroviruses 2010; 26:419-424.
83. Murphy AA, Herman A, Osinusi AO, et al. Twice weekly pegylated interferonalpha- 2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 2011; 25:1179-1187.
84. Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. (Pubitemid 351228130)
85. Italian Association for the Study of the Liver, Italian Society of Infectious, Tropical Diseases, Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010; 42:81-89.
86. Brook G, Main J, Nelson MA, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C Virus. HIV Med 2010; 11:1-30.
87. Vogel M, Ahlensteil G, Hintsche B, et al. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals. Eur J Med Res 2010; 15:102-111.